1. Scrip
  2. >>Business

Syros Goes For Reboot With New Investors And Leukemia Licensing

Bain Capital Leads $90.5m Investment

 
• By Andrew McConaghie

Syros has failed to progress in its leukemia niche since its launch a few years ago, but a new drug candidate and funding could revive its fortunes.

San Diego Conference Centre
This year's ASH congress was originally planned to take place in San Diego, but like the year's other major symposia, took place online.

Launched on the public markets four years ago as a developer of medicines targeting gene expression conditions, Syros Pharmaceuticals has struggled to convince investors of its strategy.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip